Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wuxuan Mei

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancer Treatment Reviews|June 27, 2026
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancerWei Zhou, Wuxuan Mei, Changchun Zeng
Biochimica Et Biophysica Acta. Reviews on Cancer|March 5, 2022
Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunitiesCongwang Zhang, Wuxuan Mei, Changchun Zeng
International Journal of Biological Macromolecules|April 12, 2024
Exploring FGFR signaling inhibition as a promising approach in breast cancer treatmentYan Peng, Pengfei Zhang, Wuxuan Mei, et al.
Biochemistry and Biophysics Reports|October 8, 2024
Unveiling functionality and conducting two-sample mendelian randomization on WGCNA-identified oxidative stress-related hub genes in metabolic dysfunction-associated fatty liver diseaseQian Zhu, Jiaqi Liu, Wuxuan Mei, et al.
Frontiers in Immunology|January 31, 2024
Intratumoral microbiota: implications for cancer onset, progression, and therapyJinmei Wu, Pengfei Zhang, Wuxuan Mei, et al.
European Journal of Medicinal Chemistry|June 24, 2025
Current insights and barriers in FGFR-mediated signaling in lung cancerXiaohong Liu, Wuxuan Mei, Yueru Yao, et al.
Pharmacological Research|March 3, 2024
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunitiesXiaohong Liu, Wuxuan Mei, Pengfei Zhang, et al.
Cancer Treatment Reviews|May 19, 2024
Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implicationsQian Zhu, Jiaqi Xie, Wuxuan Mei, et al.
Frontiers in Oncology|December 6, 2021
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future PerspectivesYan Peng, Wuxuan Mei, Kaidong Ma, et al.
Current Treatment Options in Oncology|August 3, 2023
Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?Yan Peng, Hongxiang Yan, Wuxuan Mei, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancer Treatment Reviews|June 27, 2026
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancerWei Zhou, Wuxuan Mei, Changchun Zeng
Biochimica Et Biophysica Acta. Reviews on Cancer|March 5, 2022
Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunitiesCongwang Zhang, Wuxuan Mei, Changchun Zeng
International Journal of Biological Macromolecules|April 12, 2024
Exploring FGFR signaling inhibition as a promising approach in breast cancer treatmentYan Peng, Pengfei Zhang, Wuxuan Mei, et al.
Biochemistry and Biophysics Reports|October 8, 2024
Unveiling functionality and conducting two-sample mendelian randomization on WGCNA-identified oxidative stress-related hub genes in metabolic dysfunction-associated fatty liver diseaseQian Zhu, Jiaqi Liu, Wuxuan Mei, et al.
Frontiers in Immunology|January 31, 2024
Intratumoral microbiota: implications for cancer onset, progression, and therapyJinmei Wu, Pengfei Zhang, Wuxuan Mei, et al.
European Journal of Medicinal Chemistry|June 24, 2025
Current insights and barriers in FGFR-mediated signaling in lung cancerXiaohong Liu, Wuxuan Mei, Yueru Yao, et al.
Pharmacological Research|March 3, 2024
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunitiesXiaohong Liu, Wuxuan Mei, Pengfei Zhang, et al.
Cancer Treatment Reviews|May 19, 2024
Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implicationsQian Zhu, Jiaqi Xie, Wuxuan Mei, et al.
Frontiers in Oncology|December 6, 2021
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future PerspectivesYan Peng, Wuxuan Mei, Kaidong Ma, et al.
Current Treatment Options in Oncology|August 3, 2023
Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?Yan Peng, Hongxiang Yan, Wuxuan Mei, et al.
Pageof 2